gsk & novartis, page-2

Hi GBR this adds more excitement to the period of the trading halt. This type of ann would certainly require confidentiality agreements from all parties. OBJ posters over the year (including me) have questioned why we have not been informed about potential partners who have been researching the use of OBJ technology to improve their product. And GSK in particular has been one of these for so long the I thought it possible OBJ technology had been rejected or passed over for a preferred technology. So fingers crossed OBJ have made an agreement with GSK.